Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...

MRNA's earnings and revenues surpass estimates in the fourth quarter of 2024. The company reiterates 2025 total revenue ...

Moderna Inc. (NASDAQ:MRNA) reported a fourth-quarter EPS loss of $(2.91), missing the consensus of $(2.62), a turnaround from ...

The "Make America Healthy Again" commission is reviewing certain vaccines as some states push to restrict the use of COVID-19 ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

Moderna is set to release its fourth-quarter earnings on Friday before the opening bell. Here's a look at what to expect in ...

Moderna MRNA incurred a loss of $2.50 per share ... Moderna currently has two marketed vaccines in its portfolio — the COVID-19 vaccine Spikevax and the recently launched respiratory syncytial ...

In the dark days of the coronavirus pandemic, Moderna (NASDAQ: MRNA) was a ray of light in more ways than one. The healthcare company's innovative Spikevax was one of the go-to vaccines that sped to ...

Moderna (NASDAQ:MRNA) stock drops ~5% as its Q4 2024 results show revenue beat but earnings miss expectations. Read more here ...

Sen. Brandon Shippy brought the bill and presented it with a slate of out-of-state physicians, many of whom have been linked ...

Declining revenue and net income, driven by reduced COVID-19 vaccine demand and RSV market ... "hold" position rather than a "sell.". Moderna (NASDAQ:MRNA), which went public at $22 in 2018 ...